Cracchiolo Andrea, Deorio James K
Department of Orthopaedic Surgery, UCLA Medical Center, Los Angeles, CA 90095-6902, USA.
J Am Acad Orthop Surg. 2008 Sep;16(9):530-40.
Development of total ankle replacements began nearly 40 years ago. The initial devices were cemented and highly constrained, and they eventually failed. These were followed by second-generation cementless ankle implants with a fixed (two-component design) or mobile (three-component design) polyethylene bearing. Currently, four ankle replacements are approved by the US Food and Drug Administration. These four-Agility, INBONE, Salto-Talaris, and Eclipse-are two-component designs; the Scandinavian Total Ankle Replacement, a three-part mobile-bearing design, has been recommended for approval by the FDA. It is anticipated to arrive in the US market in late 2008. Although interest in total ankle replacements is increasing, midterm clinical results to date are few and often have not been validated by independent practitioners. In addition, no level I or II studies have been published. Therefore, the design rationale for these implants and instruments should be carefully evaluated.
全踝关节置换术的发展始于近40年前。最初的器械采用骨水泥固定且限制较大,最终均告失败。随后出现了第二代非骨水泥型踝关节植入物,其聚乙烯承重部件有固定的(双部件设计)或活动的(三部件设计)。目前,有四种踝关节置换产品已获美国食品药品监督管理局批准。这四种产品——Agility、INBONE、Salto-Talaris和Eclipse——均为双部件设计;斯堪的纳维亚全踝关节置换术是三部件活动承重设计,已被美国食品药品监督管理局推荐批准。预计将于2008年末进入美国市场。尽管对全踝关节置换术的兴趣与日俱增,但迄今为止中期临床结果较少,且往往未经独立从业者验证。此外,尚无I级或II级研究发表。因此,应仔细评估这些植入物和器械的设计原理。